AU2012205583B2 - Novel Wnt compositions and therapeutic uses of such compositions - Google Patents

Novel Wnt compositions and therapeutic uses of such compositions Download PDF

Info

Publication number
AU2012205583B2
AU2012205583B2 AU2012205583A AU2012205583A AU2012205583B2 AU 2012205583 B2 AU2012205583 B2 AU 2012205583B2 AU 2012205583 A AU2012205583 A AU 2012205583A AU 2012205583 A AU2012205583 A AU 2012205583A AU 2012205583 B2 AU2012205583 B2 AU 2012205583B2
Authority
AU
Australia
Prior art keywords
polypeptide
wnt
wnt7a
muscle
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012205583A
Other languages
English (en)
Other versions
AU2012205583A1 (en
Inventor
Monica Hayhurst Bennett
Michael J. Fitch
Peter Flynn
Tom Tong LEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of AU2012205583A1 publication Critical patent/AU2012205583A1/en
Application granted granted Critical
Publication of AU2012205583B2 publication Critical patent/AU2012205583B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012205583A 2011-01-11 2012-01-11 Novel Wnt compositions and therapeutic uses of such compositions Active AU2012205583B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431701P 2011-01-11 2011-01-11
US61/431,701 2011-01-11
PCT/US2012/020984 WO2012097093A2 (en) 2011-01-11 2012-01-11 Novel wnt compositions and therapeutic uses of such compositions

Publications (2)

Publication Number Publication Date
AU2012205583A1 AU2012205583A1 (en) 2013-04-11
AU2012205583B2 true AU2012205583B2 (en) 2016-01-21

Family

ID=46507654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012205583A Active AU2012205583B2 (en) 2011-01-11 2012-01-11 Novel Wnt compositions and therapeutic uses of such compositions

Country Status (10)

Country Link
US (1) US9403885B2 (https=)
EP (1) EP2663576B1 (https=)
JP (1) JP5972283B2 (https=)
KR (1) KR20140038358A (https=)
CN (1) CN103476791A (https=)
AU (1) AU2012205583B2 (https=)
BR (1) BR112013017711A2 (https=)
CA (1) CA2824235A1 (https=)
SG (1) SG191933A1 (https=)
WO (1) WO2012097093A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5802195B2 (ja) 2009-04-27 2015-10-28 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
AU2012308476B2 (en) * 2011-09-16 2016-04-14 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
ES2690305T3 (es) 2011-09-16 2018-11-20 Ottawa Hospital Research Institute Composiciones de Wnt7a y métodos de utilización de las mismas
CN111193048A (zh) 2012-04-02 2020-05-22 水吉能公司 燃料电池模块及其启动、关闭和重新启动的方法
WO2013188851A1 (en) * 2012-06-14 2013-12-19 Fred Hutchinson Cancer Research Center Ex vivo expansion of myogenic stem cells by notch activation
WO2015051122A2 (en) * 2013-10-02 2015-04-09 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for purification
WO2015148923A1 (en) * 2014-03-28 2015-10-01 Ottawa Hospital Research Institute Wnt induced motility and enhanced engraftment of cells
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN108411003A (zh) * 2018-05-22 2018-08-17 华中农业大学 Wnt2基因片段作为影响猪红细胞数目性状的分子标记
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
JP2025519164A (ja) * 2022-05-27 2025-06-24 ジンキュア・コーポレイション 新規なペプチド及びその用途
CN119019529B (zh) * 2024-09-23 2026-04-10 华中农业大学 Wnt5a基因或其编码蛋白在调控宿主抗bpiv-3中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
AU3751299A (en) 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
EP2090649A1 (en) * 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
JP5802195B2 (ja) * 2009-04-27 2015-10-28 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
AU2012308476B2 (en) * 2011-09-16 2016-04-14 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOMEKADO HIDEYUKI et al., Genes to Cells, 2007, Vol. 12, pages 521-534 *
TAKADA et al., Developmental Cell, 2006, Vol. 11, pages 791-801 *

Also Published As

Publication number Publication date
CA2824235A1 (en) 2012-07-19
EP2663576A2 (en) 2013-11-20
EP2663576B1 (en) 2017-11-01
CN103476791A (zh) 2013-12-25
KR20140038358A (ko) 2014-03-28
SG191933A1 (en) 2013-08-30
WO2012097093A2 (en) 2012-07-19
EP2663576A4 (en) 2015-05-06
BR112013017711A2 (pt) 2016-08-23
US20140142046A1 (en) 2014-05-22
JP5972283B2 (ja) 2016-08-17
US9403885B2 (en) 2016-08-02
AU2012205583A1 (en) 2013-04-11
WO2012097093A3 (en) 2012-09-27
JP2014507938A (ja) 2014-04-03

Similar Documents

Publication Publication Date Title
AU2012205583B2 (en) Novel Wnt compositions and therapeutic uses of such compositions
US9873722B2 (en) Wnt compositions and therapeutic uses of such compositions
JP2014507938A5 (https=)
US20110104139A1 (en) ANGIOSTATIC COMPOSITIONS COMPRISING TRUNCATED TYROSYL-tRNA SYNTHETASE POLYPEPTIDES AND METHODS OF USING SAME
WO2009086425A1 (en) Methods for reprogramming cells to a pluripotent state and therapeutic applications related thereto
US9469679B2 (en) Neurturin molecules
US10385113B2 (en) Engineered FGF compositions and methods of use thereof
CA2960642A1 (en) Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
EP2774935B1 (en) Improved neurturin molecules
US8168749B2 (en) Stimulating neurite outgrowth using Tctex-1-related polypeptides
US8445432B2 (en) Neurturin molecules
HK1192573A (en) Novel wnt compositions and therapeutic uses of such compositions
KR20190141601A (ko) 세포 투과 펩티드 및 rpe65의 융합 단백질을 포함하는 레버 선천성 흑암시 치료용 약학적 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)